Hematology Phase 3 Deal Benchmarks — Japan (2026)

Median upfront of $181M with total deal values reaching $785M in Japan territory.

Median Upfront

$181M

Total Deal Value

$623M

Royalty Range

5.7%–10.4%

Territory Multiplier

0.09x

Understanding Hematology Deal Benchmarks at Phase 3

Phase 3 Hematology licensing deals in Japan territory command a median upfront payment of $181M, with values ranging from $115M at the low end to $239M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the hematology therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $461M to $785M, with a median of $623M. Royalty rates for hematology assets at this stage typically fall between 5.7% and 10.4% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.

The Japan territory applies a 0.09x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating japan rights should calibrate upfront expectations and milestone structures accordingly.

PRO

Full Market Analysis

Detailed deal economics, territory impact analysis, and royalty structure breakdown.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Full Benchmark Data

PRO

Full Benchmark Table

Low, median, and high ranges for upfront payments, total deal values, and royalty rates.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Comparable Deals

PRO

See All Comparable Deals

View 1 comparable Hematology transactions with upfront payments, total values, and deal structures.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Frequently Asked Questions

What is the average upfront payment for Phase 3 Hematology deals in Japan territory?

The median upfront payment for Phase 3 Hematology licensing deals in Japan territory is $181M, based on our analysis of comparable transactions. Values range from $115M for early-stage or less differentiated assets up to $239M for premium programs with strong clinical data or first-in-class mechanisms.

How does Japan territory affect Hematology deal value?

Japan rights carry a 0.09x multiplier relative to base deal economics. This means japan hematology deals are valued at a discount compared to single-country rights, reflecting the combined market opportunity, regulatory pathway, and competitive dynamics of the territory.

What royalty rates are typical for Phase 3 Hematology licensing?

Royalty rates for Phase 3 hematology assets typically range from 5.7% to 10.4% of net sales. The exact rate depends on the licensor's contribution (IP, clinical data, manufacturing), deal structure (exclusive vs. co-exclusive), and the licensee's commercialization investment. Higher royalties often correspond to lower upfront payments, and vice versa.

PRO

More Expert Insights

Territory impact analysis, royalty negotiation strategies, and deal structure guidance.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Related Benchmarks

$7M upfront

Hematology · Preclinical · Japan

$18M upfront

Hematology · Phase 1 · Japan

$55M upfront

Hematology · Phase 2 · Japan

$475M upfront

Hematology · Approved · Japan

$65M upfront

Oncology · Phase 3 · Japan

$46M upfront

Neurology/CNS · Phase 3 · Japan

$81M upfront

Immunology · Phase 3 · Japan

$111M upfront

Metabolic/Obesity · Phase 3 · Japan

Explore More

All Hematology Deals

View full therapeutic area benchmarks

Licensing Benchmarks Guide

2026 data from 1,900+ deals

Royalty Rate Benchmarks

Negotiation strategies by phase & modality

Run Custom Analysis

Pre-filled with Hematology · Phase 3

Run Your Own Benchmark

These benchmarks are starting points. Get a customized valuation for your specific asset, indication, and deal structure.

Open Deal Calculator

Cite This Data

APA

Ambrosia Ventures. (2026). Hematology Phase 3 Deal Benchmarks — Japan (2026). Retrieved from https://calculator.ambrosiaventures.co/data/hematology-phase-3-deals-japan

HTML

<a href="https://calculator.ambrosiaventures.co/data/hematology-phase-3-deals-japan">Hematology Phase 3 Deal Benchmarks — Japan (2026)</a> — Ambrosia Ventures (2026)

Embed Chart

Data sourced from 1,900+ verified biopharma transactions. Updated monthly.

Metric	Low	Median	High
Upfront Payment	$115M	$181M	$239M
Total Deal Value	$461M	$623M	$785M
Royalty Rate	5.7%	—	10.4%